Publications by authors named "Ferry Lalezari"

Claim this Profile
P
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib Treatment.
J W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, Ferry Lalezari, Daan van den Broek

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The legend of the response evaluation criteria in solid tumors: A historical overview.
Illaa Smesseim, Kevin B W Groot Lipman, Ferry Lalezari, Jacobus A Burgers, Stefano Trebeschi

Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.
Liselotte Tas, Marie B Weitemeyer, Maartje W Rohaan, Troels H Borch, Alexander C J van Akkooi, Ferry Lalezari

Br J Surg· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.
Kris G Samsom, Linda J W Bosch, Luuk J Schipper, Daoin Schout, Paul Roepman, Ferry Lalezari

Nat Protoc· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Li-Anne H Douma, Ferry Lalezari, Vincent van der Noort, Jeltje F de Vries, Kim Monkhorst

Lancet Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial.
Saskia A Cooke, Dirk de Ruysscher, Bart Reymen, Maarten Lambrecht, Gitte Fredberg Persson, Ferry Lalezari

Radiother Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group.
Sharyn I Katz, Christopher M Straus, Leonid Roshkovan, Kevin G Blyth, Thomas Frauenfelder, Ferry Lalezari

J Thorac Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Maartje W Rohaan, Troels H Borch, Joost H van den Berg, Özcan Met, Rob Kessels, Ferry Lalezari

N Engl J Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D Schouten, Ferry Lalezari

Clin Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.
Kris G Samsom, Luuk J Schipper, Paul Roepman, Linda Jw Bosch, Ferry Lalezari

J Pathol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bronchial Stenosis in Central Pulmonary Tumors Treated With Stereotactic Body Radiation Therapy.
Barbara L T Rijksen, Maddalena M G Rossi, Iris Walraven, Barbara Stam, Joost L Knegjens, Ferry Lalezari

Pract Radiat Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.
Aafke Meerveld-Eggink, Niels Graafland, Sofie Wilgenhof, Johannes V Van Thienen, Ferry Lalezari

Eur Urol Open Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
Cornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, Paul Baas, Bonne Biesma, Ferry Lalezari

Lancet Respir Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
Rosemarie de Haan, Michel M van den Heuvel, Judi van Diessen, Heike M U Peulen, Erik van Werkhoven, Ferry Lalezari

Clin Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).
Elisa A Rozeman, Warner Prevoo, Mark A J Meier, Karolina Sikorska, Trieu M Van, Ferry Lalezari

Melanoma Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.
Valsamo Anagnostou, Noushin Niknafs, Kristen Marrone, Daniel C Bruhm, James R White, Ferry Lalezari

Nat Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
Willemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, Vincent van der Noort, Jeltje F de Vries

JAMA Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk, Maarten Slagter, Hugo M Horlings, Karolina Sikorska, Koen K van de Vijver, Ferry Lalezari

Nat Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk, Maarten Slagter, Hugo M Horlings, Karolina Sikorska, Koen K van de Vijver, Ferry Lalezari

Nat Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Maria J Disselhorst, Josine Quispel-Janssen, Ferry Lalezari, Kim Monkhorst, Jeltje F de Vries

Lancet Respir Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Josine Quispel-Janssen, Vincent van der Noort, Jeltje F de Vries, Marion Zimmerman, Ferry Lalezari

J Thorac Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.
Francine E M Voncken, Berthe M P Aleman, Jolanda M van Dieren, Cecile Grootscholten, Ferry Lalezari

Strahlenther Onkol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal endobronchial tool sizes for targeting lung lesions based on 3D modeling.
Torre M Bydlon, Gerrit C Langhout, Ferry Lalezari, Koen J Hartemink, Jasper Nijkamp

PLoS One· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angioplasty with or without stent placement in the brachiocephalic artery: feasible and durable? A retrospective cohort study.
Eline S van Hattum, Jean-Paul P M de Vries, Ferry Lalezari, Jos C van den Berg, Frans L Moll

J Vasc Interv Radiol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis